Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation

@article{Antunes2015InfluenceOC,
  title={Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation},
  author={M. V. Antunes and Tatiana Aparecida da Fontoura Timm and Vanessa End de Oliveira and Dilana Staudt and S. Raymundo and Gustavo G{\"o}ssling and J. Biaz{\'u}s and J. A. Cavalheiro and D. D. Rosa and P. Wallemacq and V. Haufroid and R. Linden and G. Schwartsmann},
  journal={Therapeutic Drug Monitoring},
  year={2015},
  volume={37},
  pages={733–744}
}
Objective: In view of the large variability on therapeutic response and the multiple factors associated to tamoxifen (TAM) metabolic activation, this study aimed to evaluate the effect of CYP2D6 and CYP3A4 phenotypes, drug interactions, and vitamin D exposure on TAM metabolism in a group of breast cancer patients. Methods: Trough blood samples were collected from 116 patients. TAM and metabolites endoxifen (EDF), N-desmethyltamoxifen, and 4-hydroxytamoxifen (HTF) were measured in plasma by… Expand
Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen
Pharmacogenomics research and clinical implementation in Brazil
Pharmacogenetic testing in oncology: a Brazilian perspective
...
1
2
...

References

SHOWING 1-10 OF 53 REFERENCES
Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
Pharmacogenomics of tamoxifen therapy.
CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
CYP2D6 polymorphisms and the impact on tamoxifen therapy.
CYP2C19‐ and CYP3A4‐Dependent Omeprazole Metabolism in West Mexicans
...
1
2
3
4
5
...